View Item 

Show simple item record

Fixed- or Controlled-Dose Mycophenolate Mofetil with Standard- or Reduced-Dose Calcineurin Inhibitors: The Opticept Trial
dc.contributor.authorGaston, Robert S.en_US
dc.contributor.authorKaplan, Bruceen_US
dc.contributor.authorShah, T.en_US
dc.contributor.authorCibrik, Diane M.en_US
dc.contributor.authorShaw, L. M.en_US
dc.contributor.authorAngelis, M.en_US
dc.contributor.authorMulgaonkar, Shamkant P.en_US
dc.contributor.authorMeier-Kriesche, Herwig-Ulfen_US
dc.contributor.authorPatel, D.en_US
dc.contributor.authorBloom, R. D.en_US
dc.date.accessioned2010-06-01T21:52:29Z
dc.date.available2010-06-01T21:52:29Z
dc.date.issued2009-07en_US
dc.identifier.citationGaston, R. S.; Kaplan, B.; Shah, T.; Cibrik, D.; Shaw, L. M.; Angelis, M.; Mulgaonkar, S.; Meier-Kriesche, H.-U.; Patel, D.; Bloom, R. D. (2009). "Fixed- or Controlled-Dose Mycophenolate Mofetil with Standard- or Reduced-Dose Calcineurin Inhibitors: The Opticept Trial." American Journal of Transplantation 9(7): 1607-1619. <http://hdl.handle.net/2027.42/74911>en_US
dc.identifier.issn1600-6135en_US
dc.identifier.issn1600-6143en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/74911
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=19459794&dopt=citationen_US
dc.format.extent412008 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Incen_US
dc.rights© 2009 American Society of Transplantation and the American Society of Transplant Surgeonsen_US
dc.subject.otherCalcineurin Inhibitoren_US
dc.subject.otherCyclosporineen_US
dc.subject.otherMycophenolate Mofetilen_US
dc.subject.otherRenal Transplantationen_US
dc.subject.otherTacrolimusen_US
dc.titleFixed- or Controlled-Dose Mycophenolate Mofetil with Standard- or Reduced-Dose Calcineurin Inhibitors: The Opticept Trialen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationotherUniversity of Alabama at Birmingham, Birmingham, ALen_US
dc.contributor.affiliationotherUniversity of Arizona College of Medicine, Tucson, AZen_US
dc.contributor.affiliationotherNational Institute of Transplantation, Los Angeles, CAen_US
dc.contributor.affiliationotherUniversity of Pennsylvania Health System, Philadelphia, PAen_US
dc.contributor.affiliationotherTranslife/Florida Hospital, Orlando, FLen_US
dc.contributor.affiliationotherSaint Barnabas Medical Center, Livingston, NJen_US
dc.contributor.affiliationotherUniversity of Florida, Gainesville, FLen_US
dc.contributor.affiliationotherRoche, Nutley, NJen_US
dc.identifier.pmid19459794en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/74911/1/j.1600-6143.2009.02668.x.pdf
dc.identifier.doi10.1111/j.1600-6143.2009.02668.xen_US
dc.identifier.sourceAmerican Journal of Transplantationen_US
dc.identifier.citedreferenceLand W, Vincenti F. Toxicity-sparing protocols using mycophenolate mofetil in renal transplantation. Transplantation 2005; 80 ( 2 Suppl ): S221 – S234.en_US
dc.identifier.citedreferenceLiptak P, Ivanyi B. Primer: Histopathology of calcineurin-inhibitor toxicity in renal allografts. Nat Clin Pract Nephrol 2006; 2: 398 – 404; quiz following 404.en_US
dc.identifier.citedreferenceNankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD. Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology. Transplantation 2004; 78: 557 – 565.en_US
dc.identifier.citedreferenceFlechner SM, Goldfarb D, Modlin C et al. Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070 – 1076.en_US
dc.identifier.citedreferenceSuwelack B, Gerhardt U, Hohage H. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant 2004; 4: 655 – 662.en_US
dc.identifier.citedreferencevan Gelder T, Le Meur Y, Shaw LM et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006; 28: 145 – 154.en_US
dc.identifier.citedreferenceMerville P, Berge F, Deminiere C et al. Lower incidence of chronic allograft nephropathy at 1 year post-transplantation in patients treated with mycophenolate mofetil. Am J Transplant 2004; 4: 1769 – 1775.en_US
dc.identifier.citedreferenceGonzalez Molina M, Seron D, Garcia del Moral R et al. Treatment of chronic allograft nephropathy with mycophenolate mofetil after kidney transplantation: A Spanish multicenter study. Transplant Proc 2002; 34: 335 – 337.en_US
dc.identifier.citedreferenceOjo AO, Meier-Kriesche HU, Hanson JA et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000; 69: 2405 – 2409.en_US
dc.identifier.citedreferenceNankivell BJ, Wavamunno MD, Borrows RJ et al. Mycophenolate mofetil is associated with altered expression of chronic renal transplant histology. Am J Transplant 2007; 7: 366 – 376.en_US
dc.identifier.citedreferenceSollinger HW. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225 – 232.en_US
dc.identifier.citedreference12.  The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029 – 1037.en_US
dc.identifier.citedreference13.  European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321 – 1325.en_US
dc.identifier.citedreferenceEkberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562 – 2575.en_US
dc.identifier.citedreferencevan Gelder T, Shaw LM. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation 2005; 80 ( 2 Suppl ): S244 – S253.en_US
dc.identifier.citedreferenceNaesens M, de Loor H, Vanrenterghem Y, Kuypers DR. The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide. Transplantation 2007; 84: 362 – 373.en_US
dc.identifier.citedreferenceHale MD, Nicholls AJ, Bullingham RE et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998; 64: 672 – 683.en_US
dc.identifier.citedreferencevan Gelder T, Hilbrands LB, Vanrenterghem Y et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68: 261 – 266.en_US
dc.identifier.citedreferenceDeNofrio D, Loh E, Kao A et al. Mycophenolic acid concentrations are associated with cardiac allograft rejection. J Heart Lung Transplant 2000; 19: 1071 – 1076.en_US
dc.identifier.citedreferenceOellerich M, Shipkova M, Schutz E et al. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: Implications for therapeutic drug monitoring. Ther Drug Monit 2000; 22: 20 – 26.en_US
dc.identifier.citedreferenceWeber LT, Shipkova M, Armstrong VW et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: A report of the German Study Group on Mycophenolate Mofetil Therapy. J Am Soc Nephrol 2002; 13: 759 – 768.en_US
dc.identifier.citedreferenceParasuraman R, Yee J, Karthikeyan V, del Busto R. Infectious complications in renal transplant recipients. Adv Chronic Kidney Dis 2006; 13: 280 – 294.en_US
dc.identifier.citedreferenceBuell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005; 80 ( 2 Suppl ): S254 – S264.en_US
dc.identifier.citedreferenceLe Meur Y, Buchler M, Thierry A et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007; 7: 2496 – 2503.en_US
dc.identifier.citedreferencevan Gelder T, Silva HT, de Fijter JW et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: The Fixed-Dose Concentration-Controlled Trial. Transplantation 2008; 86: 1043 – 1051.en_US
dc.identifier.citedreferenceWillis C, Taylor PJ, Salm P, Tett SE, Pillans PI. Evaluation of limited sampling strategies for estimation of 12-hour mycophenolic acid area under the plasma concentration-time curve in adult renal transplant patients. Ther Drug Monit 2000; 22: 549 – 554.en_US
dc.identifier.citedreferenceLe Guellec C, Buchler M, Giraudeau B et al. Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy. Eur J Clin Pharmacol 2002; 57: 805 – 811.en_US
dc.identifier.citedreferenceShaw LM, Pawinski T, Korecka M, Nawrocki A. Monitoring of mycophenolic acid in clinical transplantation. Ther Drug Monit 2002; 24: 68 – 73.en_US
dc.identifier.citedreferencePawinski T, Hale M, Korecka M, Fitzsimmons WE, Shaw LM. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem 2002; 48: 1497 – 1504.en_US
dc.identifier.citedreferenceNankivell BJ, Gruenewald SM, Allen RD, Chapman JR. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995; 59: 1683 – 1689.en_US
dc.identifier.citedreferenceRacusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713 – 723.en_US
dc.identifier.citedreferenceDeters M, Kirchner G, Koal T, Resch K, Kaever V. Influence of cyclosporine on the serum concentration and biliary excretion of mycophenolic acid and 7-O-mycophenolic acid glucuronide. Ther Drug Monit 2005; 27: 132 – 138.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1600-6143.2009.02668.x.pdf
Size:
402.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.